METHOD OF TREATING NEPHROTRANSPLANT LYMPHOCELE AFTER ALLOGENIC RENAL TRANSPLANTATION Russian patent published in 2020 - IPC A61K35/16 A61K35/19 A61K8/65 A61P13/12 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to nephrology, and can be used in treating graft lymphocele after allogenic renal transplantation. Method comprises external drainage under ultrasound guidance with installation of a plastic catheter into the lymphocele cavity from the anterolateral side of the abdomen, aspiration of the contents and performing bacteriological analysis, if the test is negative, the content of total protein, creatinine and urea is evaluated if the derived values correspond to those in plasma of venous blood, then introduced into the lymphocele cavity by the installed catheter first sterilized 0.7–0.9 % solution of allogenic collagen type 1, then autologous thrombocyte-rich plasma (TRP) in ratio of 3 to 1, wherein total volume of administered preparations - allogenic collagen solution and TRP, is determined based on the volume of the lymphatic well cavity, but not more than 12 ml, then the drainage is shut off for 1 hour, after the opening of the drainage, the lymphocele cavity is aspirated, after which the drainage is switched to the self-drain with the pressure bandage application, introduction of allogenic type 1 collagen and autologous thrombocyte-rich plasma is repeated up to three sessions with an interval between administrations of 2–4 days, a day after each introduction, the volume of draining fluid is estimated, when fluid volume is 25 ml or less per day, ultrasonic control of lymphocele cavity is performed, and in case of absence of fluid accumulation in lymphocele cavity treatment is completed, in case if after third introduction volume of leakage fluid is more than 25 ml per day, wherein the volume of the flowing fluid is reduced compared to the volume measured after the first administration, the second stage of treatment is performed by introducing sterilized 0.7–0.9 % solution of type 1 allogenic collagen to three sessions in the volume, similar to volume of introduction of this preparation at the first stage, with interval between administrations of 2–4 days.

EFFECT: use of the invention enables the effective treatment of the patients after kidney transplantation complicated by the lymphocele formation in the post-transplantation period ensured by stimulating the regeneration process without tissue damage.

1 cl, 1 ex